
ONCR
Healthcare · Biotechnology · $3.3M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2023
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 16, 2023 | Before the open | -0.50 | 0.00 | +100.0% |
| Aug 3, 2023 | Time not confirmed | -0.61 | 0.00 | +100.0% |
| May 22, 2023 | After the close | -0.70 | -1.18 | -68.6% |
| Mar 24, 2023 | Before the open | -0.76 | -0.81 | -6.6% |
| Nov 2, 2022 | Before the open | -0.75 | -0.76 | -1.3% |
| Aug 4, 2022 | Before the open | -0.72 | -0.74 | -2.8% |
| May 4, 2022 | Before the open | -0.77 | -0.69 | +10.4% |
| Mar 9, 2022 | Before the open | -0.69 | -0.77 | -11.6% |
| Nov 3, 2021 | Before the open | -0.64 | -0.65 | -1.6% |
| Aug 4, 2021 | Before the open | -0.56 | -0.60 | -7.1% |
| May 4, 2021 | Before the open | -0.53 | -0.53 | 0.0% |
| Mar 10, 2021 | After the close | -0.48 | -0.56 | -16.7% |
| Nov 11, 2020 | Before the open | -0.94 |
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in…
| -21.73 |
| -2211.7% |
| Sep 2, 2020 | Time not confirmed | — | -1.14 | — |